• Masitinib is in Phase 2B/3 development phase in 8 indications simultaneously
  • Four positive Phase 2B/3 read outs, in amyotrophic lateral sclerosis (ALS), progressive forms of multiple sclerosis (PPMS & nSPMS), indolent systemic mastocytosis (ISM), and in Severe Asthma uncontrolled by oral corticosteroids
  • The indications pursued are all high unmet medical needs
  • The indications pursued combined both blockbuster potential diseases or are orphan diseases
  • Lead compound: Masitinib, kinase inhibitor selectively targeting the innate immune system through mast cells and macrophages/microglia
  • New compound: AB8939, next generation, synthetic microtubule destabilizer able to overcome multidrug resistance
  • IP 100% owned by AB Science
  • Patent protection until 2037 in ALS and between 2031 and 2036 in other indications
  • Stand-alone strategy until registration in order to retain the maximum potential for value creation during commercialization phase